Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months

By Motley Fool

Obtaining U.S. Food and Drug Administration approval for a drug, even after multiple trials in various phases, is not the easiest thing for a pharma company to do. BioMarin (NASDAQ: BMRN) knows this as well as any company that has been rejected for approval in the past. From May 2014 through July 2015, growing excitement around a potential treatment for muscular dystrophy drove the stock up by more than 150%, but it gave up almost all of those gains during the following six months as part of a sell-off across the sector, the result of news that the FDA was reviewing a strong competitor for treatment of MD.

…read more

Via:: Sports Headlines

      

Get 20% off hat purchases for ONLY $5! Join our LIDS Club @ lids.com.
%d bloggers like this: